%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-05T15:21:04Z
2024-03-28T16:50:59-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:50:59-07:00
application/pdf
Heather
2003-398.march
uuid:fee6f441-1dd1-11b2-0a00-8908275d6100
uuid:fee6f444-1dd1-11b2-0a00-aa0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(DISCUSSION)Tj
/T1_2 1 Tf
0.0462 Tw 0 -1.2 TD
[(W)79.9 (e found that patient preferences for COX-2 inhibitors are)]TJ
0.1712 Tw T*
(strongly influenced by the appeal of zero risk, consistent)Tj
0.034 Tw T*
[(with the certainty ef)17.7 (fect. Given that the only proven advan-)]TJ
0.22321 Tw T*
(tage of COX-2 inhibitors over nonselective NSAID is a)Tj
0.0688 Tw T*
(lower risk of serious GI events, these findings suggest that)Tj
0.0162 Tw T*
(the popularity of COX-2 inhibitors may be mediated in part)Tj
0.1552 Tw T*
(by a perception that these drugs eliminate, as opposed to)Tj
0.02499 Tw T*
[(reduce, the risk of toxicity)64.8 (.)]TJ
0.146 Tw 1.2 -1.2 Td
(The immense appeal of eliminating risk, in contrast to)Tj
0.1245 Tw -1.2 -1.2 Td
(reducing it, has been repeatedly seen in both medical and)Tj
0.2578 Tw T*
(nonmedical arenas. Loewenstein and colleagues recently)Tj
0.00079 Tc 0.3741 Tw T*
[(proposed that the certainty ef)17.6 (fect is mediated through)]TJ
-0.00011 Tc 0 Tw T*
(emotions)Tj
0 Tc 6.5 0 0 6.5 90.6626 560.4615 Tm
(22)Tj
-0.00011 Tc 0.0378 Tw 10 0 0 10 97.1625 557.1616 Tm
[(. )17.8 (Thus, eliminating risk \(i.e., decreasing the like-)]TJ
0.27859 Tw -4.3163 -1.2 Td
(lihood from 1% to 0\) completely eliminates anxiety or)Tj
0.0139 Tw T*
(concern, whereas decreasing risk \(i.e., decreasing the likeli-)Tj
0.0051 Tw T*
[(hood from 2% to 1%\) has little ef)17.7 (fect on the emotional feel-)]TJ
0.02499 Tw T*
(ings associated with the specific risk in question.)Tj
0.0125 Tw 1.2 -1.2 Td
(Our results must be interpreted in view of the limitations)Tj
-0.0186 Tw -1.2 -1.2 Td
[(of the study)64.8 (. First, despite our ef)17.7 (forts to recruit patients from)]TJ
0.007 Tc 0.3679 Tw T*
(diverse practices, our study sample was homogenous,)Tj
-0.00011 Tc 0.0276 Tw T*
[(thereby limiting the generalizability of our results. )17.7 (The cost)]TJ
-0.0356 Tw T*
(estimates assumed that participants would pay out-of-pocket)Tj
0.24719 Tw T*
(for their medications. For patients having a prescription)Tj
0.1953 Tw T*
(drug plan, COX-2 inhibitors dominate NSAID, since the)Tj
0 Tw T*
[(only measurable dif)17.7 (ference between the 2 options is the risk)]TJ
0.02499 Tw T*
(of serious GI events.)Tj
0.22639 Tw 1.2 -1.2 Td
[(W)79.9 (e found that preferences for COX-2 inhibitors over)]TJ
0.0938 Tw -1.2 -1.2 Td
(NSAID are strongly influenced by the appeal of zero risk.)Tj
0.2856 Tw T*
[(Few patients surveyed in this study)64.8 (, when asked to be)]TJ
0.10201 Tw T*
(responsible for the full cost of medications, prefer COX-2)Tj
0.0842 Tw T*
(inhibitors over NSAID for a 50% risk reduction in serious)Tj
0.1192 Tw T*
(GI adverse events, unless risk is eliminated. Older adults\325)Tj
0.3204 Tw T*
(willingness to pay for COX-2 inhibitors may reflect a)Tj
0.11909 Tw T*
(misperception of the risk of toxicity associated with these)Tj
0 Tw T*
(medications.)Tj
/T1_1 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 61 259.1616 Tm
[(1.)-875.1 (Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal )]TJ
1.675 -1.25 Td
(toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for)Tj
0 -1.25 TD
[(osteoarthritis and rheumatoid arthritis: the CLASS study: )54.8 (A)]TJ
T*
[(randomized controlled trial. JAMA)-220.2 (2000;284:1247-55.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Bombardier C, Laine L, Reicin )54.8 (A, et al. Comparison of upper)]TJ
1.675 -1.25 Td
(gastrointestinal toxicity of rofecoxib and naproxen in patients with)Tj
T*
(rheumatoid arthritis. N Engl J Med 2000;343:1520-8.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of)]TJ
1.675 -1.25 Td
[(rheumatoid arthritis patients to accept the risk of adverse ef)17.7 (fects.)]TJ
T*
(Rheumatology 2002;41:253-61.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Pullar )17.7 (T)74 (,)-0.1 ( )17.7 (W)39.9 (right )17.7 (V)128.9 (, Feely M. )17.7 (What do patients and rheumatologists)]TJ
1.675 -1.25 Td
[(regard as an \324acceptable\325)-201.1 (risk in the treatment of rheumatic disease?)]TJ
T*
(Br J Rheumatol 1990;29:215-8.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (O\325Brien BJ, Elswood J, Calin )54.8 (A. )17.7 (W)39.8 (illingness to accept risk in the)]TJ
1.675 -1.25 Td
(treatment of rheumatic disease. J Epidemiol Comm Health)Tj
0 Tc 0 Tw T*
(1990;44:249-52.)Tj
-0.00011 Tc 0.02499 Tw 31.325 75.671 Td
[(6.)-875.1 (Ho M, Lavery B, Pullar )17.7 (T)74 (.)-0.1 ( )17.7 (The risk of treatment: a study of)]TJ
1.675 -1.25 Td
[(rheumatoid arthritis patients\325)-201.1 (attitudes. Br J Rheumatol)]TJ
0 Tc 0 Tw T*
(1998;37:459-60.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Plous S. )17.7 (The psychology of judgement and decision making. New)]TJ
1.675 -1.25 Td
[(Y)99.8 (ork: McGraw-Hill Inc.; 1993.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Tversky )54.8 (A, Kahneman D. )17.7 (The framing of decisions and the)]TJ
1.675 -1.25 Td
[(psychology of choice. Science 1981;21)36.8 (1:453-8.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.8 (.)]TJ
1.675 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
T*
(measuring clinically important patient relevant outcomes to )Tj
T*
(anti-rheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (W)39.8 (ittink DR, Ber)17.7 (genstuen )17.7 (T)74 (. Forecasting with conjoint analysis. In:)]TJ
2.175 -1.25 Td
[(Armstrong JS, editor)54.8 (. Principles of forecasting: a handbook for)]TJ
T*
[(researchers and practitioners. Norwell, MA: Kluwer )54.8 (Academic)]TJ
T*
(Publishers; 2001.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (W)39.8 (ittink DR, Ber)17.7 (genstuen )17.7 (T)74 (. Forecasting with conjoint analysis. In:)]TJ
2.1381 -1.25 Td
[(Armstrong JS, editor)54.8 (. Principles of forecasting: a handbook for)]TJ
T*
[(researchers and practitioners. Norwell, MA: Kluwer )54.8 (Academic)]TJ
T*
(Publishers; 2001.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Johnson RM. )54.8 (Adaptive conjoint analysis. In: Proceedings, Sawtooth)]TJ
2.175 -1.25 Td
[(Software Conference on Perceptual Mapping, Conjoint )54.8 (Analysis,)]TJ
T*
(and Computer Interviewing. Ketchum, ID: Sawtooth, Software;)Tj
0 Tc 0 Tw T*
(1987:253-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Cannon GW)91.7 (, Caldwell JR, Holt P)110.8 (, et al. Rofecoxib, a specific)]TJ
2.175 -1.25 Td
[(inhibitor of cyclooxygenase 2, with clinical ef)17.7 (ficacy comparable)]TJ
T*
[(with that of diclofenac sodium: results of a one-year)39.7 (, randomized,)]TJ
T*
(clinical trial in patients with osteoarthritis of the knee and hip.)Tj
T*
[(Rofecoxib Phase III Protocol 035 Study Group. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:978-87.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Rothman )54.8 (AJ, Kiviniemi MT)73.9 (. )17.7 (T)35 (reating people with information: an)]TJ
2.175 -1.25 Td
(analysis and review of approaches to communicating health risk)Tj
T*
(information. Monogr Natl Cancer Inst 1999;25:44-51.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Mazur DJ, Hickam DH. Patients\325)-201.1 (interpretations of probability)]TJ
2.175 -1.25 Td
(terms. J Gen Intern Med 1991;6:237-40.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Laudan L. )17.7 (The book of risks. New )36.8 (Y)99.8 (ork: John )17.7 (W)39.9 (iley & Sons, Inc.;)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1994.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Langman MJ, Jensen DM, )17.7 (W)79.9 (atson DJ, et al. )54.8 (Adverse upper)]TJ
2.175 -1.25 Td
[(gastrointestinal ef)17.7 (fects of rofecoxib compared with NSAIDs.)]TJ
0 Tc 0 Tw T*
[(JAMA)-220.1 (1999;282:1929-33.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Silverstein FE, Graham DY)128.8 (, Senior JR, et al. Misoprostol reduces)]TJ
2.175 -1.25 Td
(serious gastrointestinal complications in patients with rheumatoid)Tj
T*
[(arthritis receiving nonsteroidal anti-inflammatory drugs. )54.8 (A)]TJ
T*
[(randomized, double-blind, placebo-controlled trial. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1995;123:241-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Singh G, Ramey DR, )17.7 (T)35 (riadafilopoulos G, Brown BW)91.7 (, Balise RR.)]TJ
2.175 -1.25 Td
(GI SCORE: a simple self-assessment instrument to quantify the)Tj
T*
[(risk of serious NSAID-related GI complications in RA)-220.2 (and OA)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:S75.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (T)69.9 (owheed )17.7 (TE, Hochber)17.7 (g MC. )54.8 (A)-220.1 (systematic review of randomized)]TJ
2.175 -1.25 Td
(controlled trials of pharmacological therapy in osteoarthritis of the)Tj
T*
[(knee, with emphasis on trial methodology)64.8 (. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;26:755-70.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Fraenkel L, Bogardus ST)73.9 (, )17.7 (W)39.9 (ittink DR. Understanding patient )]TJ
2.175 -1.25 Td
(preferences for the treatment of lupus nephritis using adaptive)Tj
T*
(conjoint analysis. Med Care 2001;39:1203-16.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Loewenstein GF)79.7 (, Hsee CK, )17.7 (W)79.9 (eber EU, )17.7 (W)79.9 (elch N. Risk as feelings.)]TJ
0 Tc 2.175 -1.25 Td
(Psychol Bull 2001;127:267-86.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
[(Fraenkel, et al: Pr)36.8 (efer)36.8 (ences for COX-2)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(593)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\78T"Vb%+G5@W:(FW/Q1HFo$Tm`&W1*3-o=A0Y3Kf+r@*q@Nujq.oS/_$`rXc,
Z;8Ijd%67^Tg%G3pq8B&`5]N0JrIWmd3LH7X7Sg&@SC+mnbZp*n&/lsTaQ\o10;t)
/d^o22Q8db^5"u+P*dMWU"26)'Y
b$FBr]]+]1U'PkXp-Ao6'2N^>KM#lc9'6iWYa^(KY!ke
';_FrYaZ'1bA6F.&Qf^>WsOf@PG80:mS#-4P;7$f?r!c*H^d9^b)'-to3qO[f5)kI
M_Q^R<%n"2:,sG80ZpskRJ-_CPtLG&^1lgC
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
78 0 obj
<>
endobj
51 0 obj
<>
endobj
43 0 obj
<>
endobj
40 0 obj
<>
endobj
85 0 obj
<>
endobj
97 0 obj
<>
endobj
39 0 obj
<>
endobj
71 0 obj
<>stream
HUkPgΗ/@>!eFDhuZP-""R!pI KH$!@"Z@Ezej2S/}ٍ?;?;gwy393b&0Oö/f$K7K҅IoyLx=g.Gmho{WeMxu`|l81ul 08ro9/`(K&Jy[:%oq;\J%
x;d Cۜ$g RA2JO@k;'xRqB #A'f,/h/!3yHZ$9a0A,H~}30k0f380V$#n3:F8#qsr0Y?l@e-a
֑v+;;˳>ugjx(NjĹ6'xN6GGcN:].I./eԏs̝Vqu}s!c
`?o 'āKGζЎd*UJYQiI~TeH
jP0zp$ݠPVfqx%i %2tuL]]9&('G)1[X={-TLzu5?ߕ{Zxnp㛉3fZ1ǧyȾ